ADMA Bio reports Q2 2026 results with 24% revenue growth for ASCENIV
ADMA Bio reported Q2 2026 financial results, showing strong growth in ASCENIV revenue and GAAP net income. The company reiterated FY2026 guidance and announced real-world evidence highlighting clinical improvements in treated patients.
View filing at SEC.gov →